Cargando…
Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping
BACKGROUND: Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our understanding of APOE pathophysiology and provide critical guidance for AD t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815198/ https://www.ncbi.nlm.nih.gov/pubmed/35120553 http://dx.doi.org/10.1186/s13195-022-00962-4 |
_version_ | 1784645233225498624 |
---|---|
author | Belloy, Michael E. Eger, Sarah J. Le Guen, Yann Damotte, Vincent Ahmad, Shahzad Ikram, M. Arfan Ramirez, Alfredo Tsolaki, Anthoula C. Rossi, Giacomina Jansen, Iris E. de Rojas, Itziar Parveen, Kayenat Sleegers, Kristel Ingelsson, Martin Hiltunen, Mikko Amin, Najaf Andreassen, Ole Sánchez-Juan, Pascual Kehoe, Patrick Amouyel, Philippe Sims, Rebecca Frikke-Schmidt, Ruth van der Flier, Wiesje M. Lambert, Jean-Charles He, Zihuai Han, Summer S. Napolioni, Valerio Greicius, Michael D. |
author_facet | Belloy, Michael E. Eger, Sarah J. Le Guen, Yann Damotte, Vincent Ahmad, Shahzad Ikram, M. Arfan Ramirez, Alfredo Tsolaki, Anthoula C. Rossi, Giacomina Jansen, Iris E. de Rojas, Itziar Parveen, Kayenat Sleegers, Kristel Ingelsson, Martin Hiltunen, Mikko Amin, Najaf Andreassen, Ole Sánchez-Juan, Pascual Kehoe, Patrick Amouyel, Philippe Sims, Rebecca Frikke-Schmidt, Ruth van der Flier, Wiesje M. Lambert, Jean-Charles He, Zihuai Han, Summer S. Napolioni, Valerio Greicius, Michael D. |
author_sort | Belloy, Michael E. |
collection | PubMed |
description | BACKGROUND: Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our understanding of APOE pathophysiology and provide critical guidance for AD therapies aimed at APOE. The APOE locus however remains relatively poorly understood in AD, owing to multiple challenges that include its complex linkage structure and uncertainty in APOE*2/3/4 genotype quality. Here, we present a novel APOE*2/3/4 filtering approach and showcase its relevance on AD risk association analyses for the rs439401 variant, which is located 1801 base pairs downstream of APOE and has been associated with a potential regulatory effect on APOE. METHODS: We used thirty-two AD-related cohorts, with genetic data from various high-density single-nucleotide polymorphism microarrays, whole-genome sequencing, and whole-exome sequencing. Study participants were filtered to be ages 60 and older, non-Hispanic, of European ancestry, and diagnosed as cognitively normal or AD (n = 65,701). Primary analyses investigated AD risk in APOE*4/4 carriers. Additional supporting analyses were performed in APOE*3/4 and 3/3 strata. Outcomes were compared under two different APOE*2/3/4 filtering approaches. RESULTS: Using more conventional APOE*2/3/4 filtering criteria (approach 1), we showed that, when in-phase with APOE*4, rs439401 was variably associated with protective effects on AD case-control status. However, when applying a novel filter that increases the certainty of the APOE*2/3/4 genotypes by applying more stringent criteria for concordance between the provided APOE genotype and imputed APOE genotype (approach 2), we observed that all significant effects were lost. CONCLUSIONS: We showed that careful consideration of APOE genotype and appropriate sample filtering were crucial to robustly interrogate the role of the APOE locus on AD risk. Our study presents a novel APOE filtering approach and provides important guidelines for research into the APOE locus, as well as for elucidating genetic interaction effects with APOE*2/3/4. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-00962-4. |
format | Online Article Text |
id | pubmed-8815198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88151982022-02-07 Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping Belloy, Michael E. Eger, Sarah J. Le Guen, Yann Damotte, Vincent Ahmad, Shahzad Ikram, M. Arfan Ramirez, Alfredo Tsolaki, Anthoula C. Rossi, Giacomina Jansen, Iris E. de Rojas, Itziar Parveen, Kayenat Sleegers, Kristel Ingelsson, Martin Hiltunen, Mikko Amin, Najaf Andreassen, Ole Sánchez-Juan, Pascual Kehoe, Patrick Amouyel, Philippe Sims, Rebecca Frikke-Schmidt, Ruth van der Flier, Wiesje M. Lambert, Jean-Charles He, Zihuai Han, Summer S. Napolioni, Valerio Greicius, Michael D. Alzheimers Res Ther Research BACKGROUND: Genetic variants within the APOE locus may modulate Alzheimer’s disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our understanding of APOE pathophysiology and provide critical guidance for AD therapies aimed at APOE. The APOE locus however remains relatively poorly understood in AD, owing to multiple challenges that include its complex linkage structure and uncertainty in APOE*2/3/4 genotype quality. Here, we present a novel APOE*2/3/4 filtering approach and showcase its relevance on AD risk association analyses for the rs439401 variant, which is located 1801 base pairs downstream of APOE and has been associated with a potential regulatory effect on APOE. METHODS: We used thirty-two AD-related cohorts, with genetic data from various high-density single-nucleotide polymorphism microarrays, whole-genome sequencing, and whole-exome sequencing. Study participants were filtered to be ages 60 and older, non-Hispanic, of European ancestry, and diagnosed as cognitively normal or AD (n = 65,701). Primary analyses investigated AD risk in APOE*4/4 carriers. Additional supporting analyses were performed in APOE*3/4 and 3/3 strata. Outcomes were compared under two different APOE*2/3/4 filtering approaches. RESULTS: Using more conventional APOE*2/3/4 filtering criteria (approach 1), we showed that, when in-phase with APOE*4, rs439401 was variably associated with protective effects on AD case-control status. However, when applying a novel filter that increases the certainty of the APOE*2/3/4 genotypes by applying more stringent criteria for concordance between the provided APOE genotype and imputed APOE genotype (approach 2), we observed that all significant effects were lost. CONCLUSIONS: We showed that careful consideration of APOE genotype and appropriate sample filtering were crucial to robustly interrogate the role of the APOE locus on AD risk. Our study presents a novel APOE filtering approach and provides important guidelines for research into the APOE locus, as well as for elucidating genetic interaction effects with APOE*2/3/4. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-00962-4. BioMed Central 2022-02-04 /pmc/articles/PMC8815198/ /pubmed/35120553 http://dx.doi.org/10.1186/s13195-022-00962-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Belloy, Michael E. Eger, Sarah J. Le Guen, Yann Damotte, Vincent Ahmad, Shahzad Ikram, M. Arfan Ramirez, Alfredo Tsolaki, Anthoula C. Rossi, Giacomina Jansen, Iris E. de Rojas, Itziar Parveen, Kayenat Sleegers, Kristel Ingelsson, Martin Hiltunen, Mikko Amin, Najaf Andreassen, Ole Sánchez-Juan, Pascual Kehoe, Patrick Amouyel, Philippe Sims, Rebecca Frikke-Schmidt, Ruth van der Flier, Wiesje M. Lambert, Jean-Charles He, Zihuai Han, Summer S. Napolioni, Valerio Greicius, Michael D. Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title_full | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title_fullStr | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title_full_unstemmed | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title_short | Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping |
title_sort | challenges at the apoe locus: a robust quality control approach for accurate apoe genotyping |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815198/ https://www.ncbi.nlm.nih.gov/pubmed/35120553 http://dx.doi.org/10.1186/s13195-022-00962-4 |
work_keys_str_mv | AT belloymichaele challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT egersarahj challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT leguenyann challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT damottevincent challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT ahmadshahzad challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT ikrammarfan challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT ramirezalfredo challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT tsolakianthoulac challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT rossigiacomina challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT jansenirise challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT derojasitziar challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT parveenkayenat challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT sleegerskristel challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT ingelssonmartin challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT hiltunenmikko challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT aminnajaf challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT andreassenole challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT sanchezjuanpascual challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT kehoepatrick challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT amouyelphilippe challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT simsrebecca challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT frikkeschmidtruth challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT vanderflierwiesjem challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT lambertjeancharles challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT hezihuai challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT hansummers challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT napolionivalerio challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping AT greiciusmichaeld challengesattheapoelocusarobustqualitycontrolapproachforaccurateapoegenotyping |